剖宫产胎儿取出后腹腔内氯普鲁卡因的药代动力学与耐受性
本研究为单中心、前瞻性、队列、多剂量递增研究,纳入18-50岁脊麻下剖宫产产妇,胎儿取出后子宫关闭前腹腔内给予40 mL 1%、2%或3%氯普鲁卡因(每组5例)。主要目的是确定腹腔内氯普鲁卡因的药代动力学特征(包括体内半衰期),次要目的通过测定峰血浆浓度和前瞻性评估局部麻醉药全身毒性来评价耐受性。结果显示峰血浆浓度出现在给药后5分钟,体内半衰期为5.3分钟(95%CI 4.0-6.6),未检测到局部麻醉药全身毒性临床征象。
要点
- 腹腔内氯普鲁卡因体内半衰期为5.3分钟,远长于体外半衰期(11-21秒)。
- 3组峰血浆浓度分别为64.8、28.7、799.2 ng/mL,均未出现局部麻醉药全身毒性。
- 剂量≤1200 mg胎儿取出后腹腔内给药在剖宫产中耐受性良好。
核心结论
- 腹腔内氯普鲁卡因体内半衰期(5.3分钟)比体外半衰期(11-21秒)长一个数量级以上。
- 峰血浆浓度范围为0.05-79.9 µg/kg,未出现局部麻醉药全身毒性,且远低于预设安全暴露水平(970 µg/kg)和出现临床症状的水平(2.6-2.9 mg/kg)。
- 胎儿取出后腹腔内给予剂量≤1200 mg的氯普鲁卡因在剖宫产中耐受性良好。
研究设计与样本
- 单中心、前瞻性、队列、多剂量递增研究。
- 纳入18-50岁脊麻下剖宫产产妇,胎儿取出后子宫关闭前腹腔内给予40 mL氯普鲁卡因。
- 第一队列(n=5)接受1%,第二队列(n=5)接受2%,第三队列(n=5)接受3%氯普鲁卡因溶液。
- 给药前及给药后1、5、10、20、30分钟采集产妇血样。
主要发现
- 所有3个队列峰血浆浓度均出现在腹腔内给药后5分钟。
- 1%、2%、3%氯普鲁卡因组峰血浆浓度分别为64.8 ng/mL(6.5 µg/kg)、28.7 ng/mL(2.9 µg/kg)、799.2 ng/mL(79.9 µg/kg)。
- 腹腔内给药后氯普鲁卡因体内半衰期估计为5.3分钟(95%置信区间,4.0-6.6)。
- 3个队列均未检测到局部麻醉药全身毒性临床征象。
关键数值与推荐
- 峰血浆浓度(Cmax)范围为0.05-79.9 µg/kg。
- 预设安全暴露水平为970 µg/kg。
- 出现临床症状的水平为2.6-2.9 mg/kg。
- 腹腔内氯普鲁卡因剂量≤1200 mg。
临床怎么用
- 剖宫产胎儿取出后腹腔内使用氯普鲁卡因(剂量≤1200 mg)可作为补充麻醉的选择,耐受性良好。
- 需注意腹腔内氯普鲁卡因体内半衰期(5.3分钟)远长于体外半衰期,药物吸收可能导致全身暴露。
- 尽管未观察到局部麻醉药全身毒性,仍应监测峰血浆浓度相关风险。
局限性
- 样本量小(每组5例)。
- 单中心研究。
- 未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraperitoneal chloroprocaine has been used during cesarean delivery to supplement suboptimal neuraxial anesthesia for decades. The short in vitro half-life of chloroprocaine (11-21 seconds) has been cited to support the safety of this approach. However, there are no data regarding the rate of absorption, representing patient drug exposure, through this route of administration. Accordingly, we designed a study to determine the in vivo half-life of intraperitoneal chloroprocaine and assess clinical tolerability. METHODS: We designed a single-center, prospective, cohort, multiple-dose escalation study of women 18 to 50 years of age undergoing cesarean delivery with spinal anesthesia. Chloroprocaine (40 mL) was administered after delivery of the newborn and before uterine closure. The first cohort (n = 5) received 1%, the second cohort (n = 5) received 2%, and the third cohort (n = 5) received 3% chloroprocaine solution. Maternal blood samples were obtained before administration and 1, 5, 10, 20, and 30 minutes after dosing. The primary objective was to define the pharmacokinetic profile of intraperitoneal chloroprocaine, including in vivo half-life. The secondary objective was to evaluate tolerability through determination of peak plasma concentration and prospective assessment for local anesthetic systemic toxicity. RESULTS: The peak plasma concentration occurred 5 minutes after intraperitoneal administration in all 3 cohorts: 64.8 ng/mL (6.5 µg/kg), 28.7 ng/mL (2.9 µg/kg), and 799.2 ng/mL (79.9 µg/kg) for 1%, 2%, and 3% chloroprocaine, respectively. The in vivo half-life of chloroprocaine after intraperitoneal administration was estimated to be 5.3 minutes (95% confidence interval, 4.0-6.6). We did not detect clinical signs of local anesthetic systemic toxicity in any of the 3 cohorts. CONCLUSIONS: The in vivo half-life of intraperitoneal chloroprocaine (5.3 minutes) is more than an order of magnitude greater than the in vitro half-life (11-21 seconds). However, maximum plasma concentrations of chloroprocaine (C max range, 0.05-79.9 µg/kg) were not associated with local anesthetic systemic toxicity and remain well below our predefined safe level of exposure (970 µg/kg) and levels associated with clinical symptoms (2.6-2.9 mg/kg). Therefore, our study suggests that intraperitoneal chloroprocaine, in a dosage ≤1200 mg, administered after fetal extraction, is well tolerated during cesarean delivery.
引用
- Togioka BM, Zarnegarnia Y, Bleyle LA, et al. Pharmacokinetics and Tolerability of Intraperitoneal Chloroprocaine After Fetal Extraction in Women Undergoing Cesarean Delivery. Anesth Analg. 2022. PMID: 35544759. doi:10.1213/ANE.0000000000006064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。